Compare KELYA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYA | PRLD |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | United States | United States |
| Employees | 4900 | N/A |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.1M | 391.1M |
| IPO Year | N/A | 2020 |
| Metric | KELYA | PRLD |
|---|---|---|
| Price | $15.25 | $4.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $15.00 | $5.67 |
| AVG Volume (30 Days) | ★ 336.7K | 329.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | $4.60 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $7.98 | $0.75 |
| 52 Week High | $17.75 | $5.69 |
| Indicator | KELYA | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 64.45 | 54.95 |
| Support Level | $8.48 | $3.92 |
| Resistance Level | $16.20 | $4.69 |
| Average True Range (ATR) | 0.66 | 0.33 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 33.85 | 65.94 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.